Table 1. Baseline characteristics of patients at diagnosis and last follow-up.
| Patients characteristics (n =101) | |
|---|---|
| Age at diagnosis | 64 (42–87) |
| Male | 69 (68.3%) |
| Diagnosis | |
| MBL* | 6 (5.9%) |
| CLL | 95 (94.1%) |
| Binet stage** (n =90) | |
| A | 57 (63.3%) |
| B | 23 (25.6%) |
| C | 10 (11.1%) |
| B-symptoms (n = 67) | 6 (9%) |
| Adenopathies (n = 71) | 37 (52.1%) |
| Splenomegaly (n =68) | 12 (17.6%) |
| Hepatomegaly (n =68) | 6 (8.8%) |
| Absolute white blood cell count (× 109/L) (n = 71) | 20 (3.8–372) |
| Absolute lymphocyte count (× 109/L) (n =68) | 15 (1–369) |
| Hemoglobin (g/dL) (n = 68) | 13.8 (7–18) |
| Platelets (×109/L) (n = 68) | 196 (2–356) |
| Lactate dehydrogenase (IU/L) (n = 64) | 335 (180–959) |
| Beta-2 microglobulin (mg/L) (n = 59) | 2.4 (1–8.4) |
| Unmutated IGHV (n =32) | 27 (84.4%) |
| Mutated NOTCH1 (n = 19) | 2 (10.5%) |
| Last follow-up | |
| Treated patients (n =97) | 81 (83.5%) |
| Time to first treatment (months, 95% CI) (n = 96) | 23 (14–33) |
| Deaths | 66 (65.3%) |
| Overall survival (months, 95% CI) (n = 99) | 88 (67–108) |
| Follow-up (months) | 62 (0–201) |
Values are given as median (range) or number (%). Hemoglobin is expressed as mean (range).
*
Although 6 patients were diagnosed as MBL (monoclonal B-cell lymphocytosis), all of them had already progressed to CLL at the time of study.
**
Some centers only provided information regarding the Binet stage without the physical examination and the analytical parameters.